» Articles » PMID: 20360855

An Expanded Self-antigen Peptidome is Carried by the Human Lymph As Compared to the Plasma

Overview
Journal PLoS One
Date 2010 Apr 3
PMID 20360855
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The pre-nodal afferent lymph is the fluid which directly derives from the extracellular milieu from every parenchymal organ and, as it continues to circulate between the cells, it collects products deriving from the organ metabolism/catabolism. A comprehensive qualitative and quantitative investigation of the self-antigenic repertoire transported by the human lymph is still missing.

Methodology/principal Findings: A major difference between lymph and plasma could be visualized by FPLC and 2D gel in the amount of low molecular weight products corresponding to peptide fragments. Naturally processed peptides in normal pre-nodal human lymph were then fractionated by HPLC and characterized by multidimensional mass spectrometry. Analysis of more then 300 sequences identified self-peptides derived from both intracellular and extracellular proteins revealing the variety of catabolic products transported by human lymph. Quantitative analysis established that at least some of these peptides are present in the circulating lymph in nanomolar concentration.

Conclusions/significance: The peptidome, generated by physiological tissue catabolism and transported by the pre-nodal lymph, is in addition to the self-peptidome generated in endosomal compartment. Unlike self antigen processed by local or nodal APC, which mostly produce epitopes constrained by the endosomal processing activity, self antigens present in the lymph could derived from a wider variety of processing pathways; including caspases, involved in cellular apoptosis, and ADAM and other metalloproteinases involved in surface receptor editing, cytokines processing and matrix remodeling. Altogether, expanding the tissue-specific self-repertoire available for the maintenance of immunological tolerance.

Citing Articles

Multi-site Ultrasound-guided Fine Needle Aspiration to Study Cells and Soluble Factors From Human Lymph Nodes.

Al-Diwani A, Agrawal D, Sheerin F, Board C, Irani S, Pollock K Curr Protoc. 2024; 4(11):e70063.

PMID: 39579041 PMC: 11585077. DOI: 10.1002/cpz1.70063.


Role of the afferent lymph as an immunological conduit to analyze tissue antigenic and inflammatory load.

Nanaware P, Khan Z, Clement C, Shetty M, Mota I, Seltzer E Cell Rep. 2024; 43(6):114311.

PMID: 38848214 PMC: 11233987. DOI: 10.1016/j.celrep.2024.114311.


Same yet different - how lymph node heterogeneity affects immune responses.

Cruz de Casas P, Knopper K, Sarkar R, Kastenmuller W Nat Rev Immunol. 2023; 24(5):358-374.

PMID: 38097778 DOI: 10.1038/s41577-023-00965-8.


Nanotechnologies for Physiology-Informed Drug Delivery to the Lymphatic System.

Maisel K, McClain C, Bogseth A, Thomas S Annu Rev Biomed Eng. 2023; 25:233-256.

PMID: 37000965 PMC: 10879987. DOI: 10.1146/annurev-bioeng-092222-034906.


Molecular Determinants Regulating the Plasticity of the MHC Class II Immunopeptidome.

Santambrogio L Front Immunol. 2022; 13:878271.

PMID: 35651601 PMC: 9148998. DOI: 10.3389/fimmu.2022.878271.


References
1.
Tanabe S . Epitope peptides and immunotherapy. Curr Protein Pept Sci. 2007; 8(1):109-18. DOI: 10.2174/138920307779941569. View

2.
Kaldjian E, Gretz J, Anderson A, Shi Y, Shaw S . Spatial and molecular organization of lymph node T cell cortex: a labyrinthine cavity bounded by an epithelium-like monolayer of fibroblastic reticular cells anchored to basement membrane-like extracellular matrix. Int Immunol. 2001; 13(10):1243-53. DOI: 10.1093/intimm/13.10.1243. View

3.
Savina A, Amigorena S . Phagocytosis and antigen presentation in dendritic cells. Immunol Rev. 2007; 219:143-56. DOI: 10.1111/j.1600-065X.2007.00552.x. View

4.
Larche M, Wraith D . Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med. 2005; 11(4 Suppl):S69-76. DOI: 10.1038/nm1226. View

5.
Melief C, van der Burg S . Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008; 8(5):351-60. DOI: 10.1038/nrc2373. View